ChristopherHanyoungLieuMD

Associate Professor, University of Colorado School of Medicine

Overview of Dr. Lieu

Dr. Christopher Lieu is an oncologist in Aurora, CO and is affiliated with University of Colorado Hospital. He received his medical degree from Wake Forest School of Medicine of Wake Forest Baptist Medical Center and has been in practice 13 years. He is one of 127 doctors at University of Colorado Hospital who specialize in Oncology. He has more than 90 publications and over 500 citings.

Office
12801 E 17th Ave
Rm 8126
Aurora, CO 80045
Book by Phone+1(720) 818-9396

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ColoradoResidency, Internal Medicine, 2004 - 2007
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2004

Certifications & Licensure

TX State Medical License 2008 - 2026
CO State Medical License 2007 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
Completed
Phase 1
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer Start of enrollment: 2013 Feb 12
Terminated
Phase 1, Phase 2
Metabiomics Colon Cancer Clinical Research Study Start of enrollment: 2019 Mar 01
Unknown status
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Start of enrollment: 2014 Aug 05
Active, not recruiting
Phase 1
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Start of enrollment: 2015 Dec 01
Terminated
Phase 2
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Start of enrollment: 2018 Oct 10
Recruiting
Phase 1
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
Recruiting
Phase 1, Phase 2
Roles: Contact
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Start of enrollment: 2022 Mar 21
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

266 citations
Neuroendocrine and adrenal tumors, version 2.2021
Manisha H. Shah, Whitney S. Goldner, Al B. Benson, Emily K. Bergsland, Lawrence S. Blaszkowsky
Journal of the National Comprehensive Cancer Network. 2021-07-28
373 citations
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with...
Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng
Journal of Clinical Oncology. 2010-01-20
50 citations
Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American society for clinical pathology, college of American pathologists, association...
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne W. Grody, Allison M. Cushman-Vokoun
Archives of Pathology & Laboratory Medicine. 2017-02-06

Journal Articles

Association of Cancer Immunotherapy with Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis
Sharon Solomon, Christopher H Lieu, Ashvini Reddy, Leisha A Emens, S Lindsey Davis, Lingmin He, JAMA

Lectures

Addressing Survivorship in Cancer Care
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

More Younger People Are Getting Colonoscopies, a New Study SuggestsOctober 3rd, 2024
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel SaysSeptember 27th, 2024
Colorectal Cancer in Young PeopleMarch 21st, 2023
Join now to see all